For example, non-small-cell lung cancer (NSCLC) patients with high TP53 expression have been found to have greater survival benefit from adjuvant cisplatin [3], while PD-L1 protein expression has demonstrated utility in patient selection for treatment with immune checkpoint inhibitors [4]. Here, TP53 is linked to non-small cell lung carcinoma.